skip to navigation skip to content


Back to Ventures

These ventures have just started at Accelerate Cambridge. They are at various stages of development, with some having already raised their first seed round.

AI Agents

The AI Agents's "iSeer" platform app will serve users who want to purchase products or services that match closely their profile and value system. As successful companies try to build virtual ecosystems for their customers, our app will help sellers to target their audience without compromising its privacy.

Visit the AI Agents website

Cambridge Data Lab

Genomic summary data is being increasingly used to de-risk pharmaceutical development and reduce clinical trial failure rates. We are democratising access to genomic data by creating an index of all public and private genomic summary datasets. Our suite of algorithms will clean genomic summary data and make this information easily indexable. We will enable collaboration by connecting holders of private genomic summary datasets to organisations who have the resources to implement the value of genomic summary datasets in drug development.

Cambridge Data Lab logo


Computationally designed, personalised, three dimensional (3D) models for corrective, congenital cardiac surgery in neonates.


D-Art is about smart healthcare for artworks.

Artworks have been built over centuries using materials that deteriorate due to natural ageing, exposure to light and human activities. The conservation process is expensive and time-consuming, limiting its presentation to visitors. The lack of skilled conservators and technologies for conservation has been well-known in the field. Current general solutions to these issues are centred around climate control, which is very expensive and not environmental friendly. It is therefore essential to equip heritage institutes with cheap but effective automatic health check system that can be easily tailored to individual objects.

We provide a system that is easy to deploy and affordable to heritage institutes. It brings together the capacity of image analysis, artificial intelligence and predictive models. Our algorithm can identify damages, track their evolution over time and provide dynamic assessments and recommendations for treatment needs (outputs of predictive models using machine learning techniques). This allows the institutes to put limited curator efforts into artworks that require immediate attention, and to better plan for prompt intervention time. This can greatly reduce operational cost and optimise collection management.

Our team consists of scientific experts in museum studies with over 10 years of combined experiences in imaging, data processing and structural health monitoring. We have a large international network of professional conservators in the largest institutes such as the English Heritage and Wallace Collection (UK), Rijksmuseum (Netherlands) and the Louvres (France).

D-Art logo


Deepskin are developing novel imaging tools to understand and diagnose skin disease.


As chemotherapy suppresses the immune system, even a mild illness can be fatal for chemotherapy patients. The suppression of a white blood cell known as the neutrophil, can lead to neutropenic sepsis, a life-threatening medical emergency. Therefore, chemotherapy patients with even mild signs of infection at home are brought into hospital for blood tests to check their neutrophil levels and, while awaiting results, given intravenous antibiotics as a precaution. Six in 10 patients turn out to have normal neutrophil counts, and therefore did not necessarily need to attend hospital, costing the NHS approximately £40 million each year.

NeutroCheck was launched to develop a transformative new medical device, NeutroCheck, presenting tangible efficiencies in patient care and healthcare resource, both financial and human. The device will be used in the patient’s home to give a near-instant measure of the patient’s neutrophil levels using blood from a small pin-prick. The NeutroCheck device is designed to be portable and easy-to-use in a home environment.

Our focus is to produce a fast, reliable and low-cost device which would improve safety and quality of life for cancer patients worldwide, whilst saving healthcare institutions such as the NHS millions of pounds each year from substantially reducing hospital visits.

NeutroCheck logo

Pinpoint Oncology

Pinpoint Oncology provides a pharmacogenomic test for cancer treatment


QBio is building a pioneering platform to deliver targeted, personalised antibiotics, faster.

Repeat XP

The Repeat Experience (XP) is a Cambridge-based startup fighting food insecurity.

The team is developing a platform that guarantees the user to gain and maintain a healthy diet while experiencing constraints to achieve it, such as lack of time, knowledge and money. Repeat XP applies machine learning to maximise the user grocery expenditure, buying in the most efficient and intelligent way. It also provides the user with the knowledge to have a healthy and diverse diet and saves them some time on planning and preparation.

In other words, Repeat XP is a personal diet and grocery shopping assistant! Repeat XP aims to create a social impact, and will be free of charge, enabling everyone to enjoy the benefits of The Repeat Experience.

The Repeat Experience logo


Sura is a personal medicine platform that tailors and monitors oral contraceptive use based on every woman's unique biological profile; medical history, mental health, genetics and hormone levels.


Unlimitech are creating next-level fitness trackers for highly-active sportspeople.

Unlimitech aims to democratise the access to high-quality fitness information through a new category of specialised fitness trackers and companion software services. With our solutions, and for the first time, everyone can get access to the same kind of powerful insights usually reserved for elite athletes, without having to break the bank.

Unlimitech Cambridge logo